Monocular Action Video Game Treatment of Amblyopia

Sponsor
Universitat Politècnica de Catalunya (Other)
Overall Status
Recruiting
CT.gov ID
NCT04313257
Collaborator
Hospital Mutua de Terrassa (Other), Parc Sanitari Sant Joan de Déu (Other)
80
1
2
38.5
2.1

Study Details

Study Description

Brief Summary

This study evaluates the effectiveness of the monocular treatment with action video-games in comparison with the occlusion therapy alone in amblyopic patients, and the satisfaction with the different evaluated treatments.

Condition or Disease Intervention/Treatment Phase
  • Other: Monocular Active Occlusion
  • Other: Monocular Passive Occlusion
N/A

Detailed Description

Amblyopia is the condition in which there is a decrease in monocular visual acuity or, less frequently, binocular, in absence of structural anomalies or ocular pathology. It is a reversible condition that affects up to 5% of the population, and that is the result of an abnormal visual experience during the most sensitive period of visual development.

The aim of this study is reviewing, analyzing and, if applicable, updating the current treatment model for amblyopia.

A randomized clinical trial will be performed to evaluate the effectiveness of the monocular treatment with action video-games in comparison with the occlusion therapy alone in amblyopic patients, and the satisfaction with the different evaluated treatments. The participants will be distributed in two groups. The first group will include those participants who will follow a daily occlusive treatment and the second group will include patients who will be treated with monocular therapy with video-games.The sample will include subjects between 4 to 10 years old with a diagnosis of refractive and / or strabismic amblyopia.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized clinical trialRandomized clinical trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Monocular Action Video Game Versus Passive Occlusion In The Treatment Of Amblyopia: A Randomized Controlled Trial
Actual Study Start Date :
Sep 17, 2019
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Passive Occlusion

This arm will include those participants who will follow a daily occlusive treatment of 2 hours.

Other: Monocular Passive Occlusion
Occlusion treatment of two hour daily.

Experimental: Active Occlusion

This arm will include patients who will be treated with monocular therapy with video-games of one hour on a daily regimen.

Other: Monocular Active Occlusion
Occlusion treatment of one hour daily with action video game.

Outcome Measures

Primary Outcome Measures

  1. Change from baseline visual acuity (VA) at 14 hours , 28 hours , and 42 hours comparing passive occlusion vs active occlusion (with action video games). [Baseline and 14, 28 and 42 hours post treatment.]

    Visual Acuity (VA in logMAR) will be evaluated by E Snellen Test through an Ipad and the app AmblyopiaVA. The AmblyopiaVA test is designed based on the standard protocol for measuring Visual Acuity in children with Amblyopia.The measure will be performed at 2 m.

  2. Change from baseline stereopsis (ST) at 14 hours , 28 hours , and 42 hours comparing passive occlusion vs active occlusion (with action video games). [Baseline and 14, 28 and 42 hours post treatment.]

    Stereopsis (ST in logMAR) will be evaluated by a Multiple Random Points test through an Ipad, the app StereoTAB and anaglyphic glasses. The measures will be performed at 50 cm.

  3. Change from baseline contrast sensitivity function (CSF) at 14 hours , 28 hours , and 42 hours comparing passive occlusion vs active occlusion (with action video games). [Baseline and 14, 28 and 42 hours post treatment.]

    The effect of treatment on Contrast Sensitivity Function (CSF in logMAR) will be evaluated by ClinicCFS test using sine grids of four different spatial frequencies: 3, 6, 12 and 18 cpd.

Secondary Outcome Measures

  1. Satisfaction assessed by an ordinal questionnaire designed based on the Treatment Satisfaction Questionnaire for Medication (TSQM). [42 hours]

    Satisfaction assessed by an ordinal questionnaire (1 to 5, as 1 the lowest satisfaction and 5 the highest satisfaction),based on the TSQM (Treatment Satisfaction Questionnaire for Medication) version 1.4 to provide data regarding the degree of satisfaction and sensation of parents and children in relation to treatment.

  2. Rate of Compliance comparing passive occlusion vs active occlusion (with action video games) assessed by Google Analytics and written questionnaire. [Baseline and 14h, 28h and 42 hours.]

    Rate of Compliance assessed through the registration of parent-reported adherence and log file data in Google Analytics (descriptive scale of time in hours/day) for active group and parent's questionnaire for passive group (subjective scale in hours/day)

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years to 10 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 4-10 years old

  • Anisometropic amblyopia

  • Strabismic amblyopia or mixed

  • Interocular visual acuity (VA) difference of at least 0.2 logMAR

  • No history of eye surgery

Exclusion Criteria:
  • Non-comitant and/or large constant strabismus (>30 prism diopters)

  • Any ocular pathological condition or nystagmus

Contacts and Locations

Locations

Site City State Country Postal Code
1 Laura Asensio Jurado Barcelona Spain

Sponsors and Collaborators

  • Universitat Politècnica de Catalunya
  • Hospital Mutua de Terrassa
  • Parc Sanitari Sant Joan de Déu

Investigators

  • Principal Investigator: Laura Asensio Jurado, MsC, Universitat Politècnica de Catalunya
  • Study Director: Marc Argilés Sans, PhD, Universitat Politècnica de Catalunya
  • Study Director: Lluïsa Quevedo i Junyent, PhD, Universitat Politècnica de Catalunya

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Laura Asensio Jurado, Principal Investigator, Universitat Politècnica de Catalunya
ClinicalTrials.gov Identifier:
NCT04313257
Other Study ID Numbers:
  • PhDLAJE1
First Posted:
Mar 18, 2020
Last Update Posted:
May 24, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Laura Asensio Jurado, Principal Investigator, Universitat Politècnica de Catalunya
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 24, 2022